NanoSmart Pharmaceuticals

NanoSmart's multi-platform technology enables the next generation of biopharmaceuticals for the treatment of all solid tumor cancers, including: breast cancer, prostate cancer, lung cancer, and rare pediatric cancers. NanoSmart Pharmaceuticals has developed several novel drug delivery platforms with the potential to enhance the safety and efficacy of an almost unlimited number of existing anticancer drugs. Since NanoSmart's human antibody is non-tumor marker specific (targeting necrotic regions present in all solid tumors), we offer the industry a unique opportunity to significantly improve existing products and effectively expand the product pipeline while minimizing clinical and regulatory risks.